Q&A with Carolyn S.P. Lam.
CSP, L. (2026). Q&A with Carolyn S.P. Lam.. Med (New York, N.Y.). https://doi.org/10.1016/j.medj.2026.101191
CSP L. Q&A with Carolyn S.P. Lam.. Med (New York, N.Y.). 2026; doi: 10.1016/j.medj.2026.101191
CSP L. Q&A with Carolyn S.P. Lam.[J]. Med (New York, N.Y.). 2026. DOI: 10.1016/j.medj.2026.101191.
@article{csp2026,
author = {Lam CSP},
title = {Q&A with Carolyn S.P. Lam.},
journal = {Med (New York, N.Y.)},
year = {2026},
doi = {10.1016/j.medj.2026.101191},
note = {PMID: 42431182},
}
TY - JOUR AU - Lam CSP TI - Q&A with Carolyn S.P. Lam. T2 - Med (New York, N.Y.) PY - 2026 DO - 10.1016/j.medj.2026.101191 AN - PMID:42431182 ER -
Professor Carolyn S.P. Lam is a senior consultant cardiologist at the National Heart Centre Singapore, where she founded Singapore's first women's heart clinic, and a tenured full professor at Duke-NUS Medical School. She is co-founder of Us2.ai, an award-winning startup applying artificial intelligence to echocardiography, with regulatory clearance across more than 35 countries. Her research spans heart failure with preserved ejection fraction, sex differences in cardiovascular disease, and Asian heart failure phenotypes. She is principal investigator of the ASIAN-HF registry and chairs several large international trials, including SURMOUNT-MMO, LIBREXIA-AF, HF-POLARIS, and CASTLE-HFpEF. She is co-chair of the 2024 KDIGO Controversies Conference and a leading voice on women's heart health and AI-enabled cardiovascular care.